News for 3SBio Inc. (TRSBF)

SHENYANG, China, Feb. 20, 2025 (GLOBE NEWSWIRE) -- On February 18, the Launch Ceremony and Investment Promotion Event for the Development of Shenyang as An International Central City in Northeast Asia opened with great fanfare. Hosted by the Shenyang Municipal People's Government with the theme of 'Hand in Hand to Share Opportunities, United in Heart for A Win-win Future,' the event aimed to showcase Shenyang's inclusiveness and willingness in embracing opening-up and cooperation, so as to attract enterprises at home and abroad to participate in the building of an international central city in Northeast Asia.

ChinaBio's latest week in review covers Hengrui out-licensing next-gen PARP1 to Merck KGaA for $1.7 Billion. Click here to read more.

Increasing usage of Fc fusion proteins for in vivo and in vitro research and increasing use as drugs are some key factors driving global Fc fusion protein...

/PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached...

/PRNewswire/ -- The global immunology market size is estimated to grow by USD 56.07 billion from 2022 to 2027, according to Technavio. The market is estimated...

/PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today announced its 2022 annual results. In 2022, 3SBio's core biopharmaceutical...

Visiongain has published a new report entitled Biosimilars and Follow-on Biologics 2023-2033. It includes profiles of Biosimilars and Follow-on Biologics...

Key Takeaways: Cutia Therapeutics has filed for a Hong Kong listing, even as its losses grow following the launch of its first two hair loss drugs last year The company is backed by a number of big-name investors, including WuXi AppTec’s venture arm, Yunfeng Capital and Sequoia Capital By Emily Chan

Visiongain has published a new report entitled Biosimilars and Follow-on Biologics 2023-2033. It includes profiles of Biosimilars and Follow-on Biologics...

Visiongain has published a new report entitled Biosimilar Monoclonal Antibodies 2022-2032. It includes profiles of Biosimilar Monoclonal Antibodies and...

PHILADELPHIA, Oct. 03, 2022 -- AnPac Bio-Medical Science Co., Ltd. , a biotechnology company with operations in the United States and China focused on early cancer screening and detection, today... | October 3, 2022

/PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2021 interim results. 3SBio maintained strong performance in core...